申请人:Takeda Chemical Industries, Ltd.
公开号:US04943645A1
公开(公告)日:1990-07-24
A novel benzoquinone derivative of the general formula: ##STR1## [wherein R.sub.1 and R.sub.2 are the same or different and each is methyl or methoxy; n is an integer of 0 to 21; m is 0 or 1, Z is a group of the formula: ##STR2## (wherein R.sub.3 and R.sub.4 are the same or different and each is hydrogen or an alkyl group which may optionally be substituted or, R.sub.3 and R.sub.4 together with the adjacent nitrogen atom form a morpholino group), a group of the formula: --COR.sub.5 (wherein R.sub.5 is an .alpha.-amino acid residue or a substituted or unsubstituted glucosamine residue), a group of the formula: ##STR3## (wherein R.sub.6 is a divalent hydrocarbon group of 1 to 3 carbon atoms), a group of the formula: ##STR4## (wherein R.sub.6 has the same meaning as defined above) or a group of the formula: ##STR5## (wherein l is an integer of 1 to 4 and R.sub.7 is hydroxy, methoxy or methyl)] has protocollagen-proline hydroxylase inhibiting activity, collagen biosynthesis inhibiting activity and 5-lipoxygenase suppressant activity, and is useful for the prevention and treatment of such diseases as pulmonary fibrosis, hepatocirrhosis, nephrosclerosis, arteriosclerosis, scleroderma, myelofibrosis and chronic arthritis or for the prevention and treatment of asthma, allergic rhinitis, urticaria, etc.
一种新型苯醌衍生物的一般式:##STR1## [其中R.sub.1和R.sub.2相同或不同,每个都是甲基或甲氧基; n为0至21的整数;m为0或1,Z为以下式的基团:##STR2##(其中R.sub.3和R.sub.4相同或不同,每个是氢或可选地被取代的烷基基团,或者R.sub.3和R.sub.4与相邻的氮原子一起形成吗啡环基团),以下式的基团:--COR.sub.5(其中R.sub.5是α-氨基酸残基或取代或未取代的葡萄糖胺残基),以下式的基团:##STR3##(其中R.sub.6是1至3个碳原子的双价碳氢基团),以下式的基团:##STR4##(其中R.sub.6具有上述定义的相同含义)或以下式的基团:##STR5##(其中l为1至4的整数,R.sub.7为羟基、甲氧基或甲基)。该化合物具有原胶原脯氨酸羟化酶抑制活性、胶原合成抑制活性和5-脂氧合酶抑制剂活性,可用于预防和治疗肺纤维化、肝硬化、肾硬化、动脉硬化、硬皮病、骨髓纤维化和慢性关节炎等疾病,或预防和治疗哮喘、过敏性鼻炎、荨麻疹等疾病。